EmpowerPharm
EmpowerPharm is an early-stage Canadian pharmaceutical company developing prescription CBD tablets for anxiety sufferers. In May 2024, it acquired $52 million of sterile manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma.
- Company typePrivate
- Founded2018
- HeadquartersBurlington, Canada
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What EmpowerPharm does
EmpowerPharm is an early-stage pharmaceutical company founded in 2018 and headquartered in Burlington, Canada. The company's stated focus is developing prescription CBD tablets targeted at anxiety sufferers, positioning it within the cannabinoid-based therapeutics segment of the pharmaceutical industry. The firm is privately held, and its commercial product line and revenue stream have not been disclosed in the available source data, indicating pre-commercial or early-commercial operations.
In May 2024, EmpowerPharm executed a $52 million acquisition of manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma Ltd., explicitly to strengthen its capabilities in sterile medication manufacturing. This transaction represents the most material strategic action on record and suggests a vertical-integration strategy aimed at bringing production capacity in-house ahead of broader pharmaceutical operations. The acquisition implies the company is positioning itself to manufacture sterile pharmaceutical products at scale, which extends beyond its initial CBD tablet focus into broader sterile drug manufacturing.
The company is led by Aubrey Dan, who serves as Founder, Chairman, and Co-CEO, with Lennie Ryer as Director and Chair of the Audit Committee. The limited leadership disclosure, absence of headcount figures, and lack of disclosed funding rounds or revenue figures constrain visibility into the company's organizational scale and capital structure. Ownership details, institutional investors, and the regulatory status (e.g., Health Canada or FDA approval status) of its prescription CBD product are not available in the source data.
EmpowerPharm firmographics
Firmographics- Name
- EmpowerPharm
- Legal name
- Empower Pharma
- Website
- https://empowerpharm.ca
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- EmpowerPharm is an early-stage Canadian pharmaceutical company developing prescription CBD tablets for anxiety sufferers. In May 2024, it acquired $52 million of sterile manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma.
- Ownership category
- akta.pro rank
EmpowerPharm industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
- akta.pro secondary industry
- Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)
Keywords
Where EmpowerPharm is headquartered
LocationHeadquarters
- HQ city
- Burlington
- HQ country
- Canada
- HQ region
- North America
Markets served
EmpowerPharm business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain
EmpowerPharm product offering
Product offeringCore offering
EmpowerPharm develops and manufactures prescription CBD tablets intended for anxiety sufferers. In May 2024, the company acquired sterile medication manufacturing assets from Eugia US LLC (a subsidiary of Aurobindo Pharma) for $52 million, enabling in-house pharmaceutical production capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- Prescription CBD Tablets for Anxiety Prescription-grade CBD tablets developed by EmpowerPharm for the treatment of anxiety sufferers. The product is intended for individual patients receiving the medication via physician prescription.
Companies that use EmpowerPharm
Customer profileIdeal customer profiles1 record
EmpowerPharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
EmpowerPharm partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Eugia US LLC (Aurobindo Pharma Ltd. subsidiary)coreEmpower Pharma acquired manufacturing assets from Eugia US LLC for $52 million in May 2024. This acquisition was specifically designed to strengthen Empower Pharma's capabilities in sterile medication manufacturing, enhancing its production capacity in this specialized pharmaceutical segment.
Scale indicators1 record
Recent moves1 record
Expansion highlights2 records
EmpowerPharm competitors and assessment
Company assessmentBroad incumbents
- Canopy Growth: Diversified cannabis operator that has pursued pharmaceutical CBD product launches in Canada and other markets. Comparable in ambition to combine cannabis-derived actives with regulated pharmaceutical pathways.
- Jazz Pharmaceuticals: CNS-focused specialty pharma that acquired GW Pharmaceuticals and now markets Epidiolex (prescription CBD). A broader incumbent demonstrating scale economics for the same niche EmpowerPharm is targeting.
- Aurobindo Pharma: Global generics manufacturer whose subsidiary (Eugia US) sold sterile manufacturing assets to EmpowerPharm for $52M. Broader incumbent peer given manufacturing overlap and demonstrated commercial diligence into the EmpowerPharm thesis.
- Tilray Brands: Large publicly-traded cannabis company with both consumer CBD and a pharmaceutical division. Broad incumbent across the cannabis-to-pharma continuum, providing category context for EmpowerPharm's prescription strategy.
Direct peers
- GW Pharmaceuticals (Jazz Pharmaceuticals): Pioneer in prescription cannabinoid medicines (e.g., Epidiolex/Epidyolex). The closest direct comparable to EmpowerPharm's prescription CBD pharmaceutical strategy and the validation benchmark for the category.
- Zynerba Pharmaceuticals: Specialty cannabinoid pharmaceutical developer focused on transdermal CBD formulations for CNS indications (e.g., Fragile X, anxiety). Closely mirrors EmpowerPharm's prescription CBD + anxiety therapeutic positioning.
- Botanix Pharmaceuticals: Clinical-stage cannabinoid pharmaceutical company developing prescription CBD formulations for dermatology and other indications. Direct peer in CBD drug development with comparable stage profile to EmpowerPharm.
Emerging players
- Aphria (now part of Tilray): Medical-cannabis focused operator pursuing pharmaceutical-grade positioning. Comparable to EmpowerPharm in the cannabinoid-pharma crossover but focused more on dried flower and oil formats than tablet dosage forms.
- Charlotte's Web: Vertically integrated hemp-derived CBD wellness company that has pursued FDA pathway engagement for CBD products. Compares to EmpowerPharm in CBD focus, though oriented to wellness/supplement channels rather than prescription pharma.
- PureForm Global: Specialty pharmaceutical company focused on the development and commercialization of branded generics and novel delivery formats. Comparable in stage and in targeting regulated finished dosage form manufacturing, analogous to EmpowerPharm's tablet focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
EmpowerPharm social profiles
Digital presenceEmpowerPharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
EmpowerPharm leadership team
Management profileNumber of profiles
Profiles2 records
EmpowerPharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EmpowerPharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EmpowerPharm
What does EmpowerPharm do?
EmpowerPharm develops and manufactures prescription CBD tablets intended for anxiety sufferers. In May 2024, the company acquired sterile medication manufacturing assets from Eugia US LLC (a subsidiary of Aurobindo Pharma) for $52 million, enabling in-house pharmaceutical production capabilities.
Is EmpowerPharm a public or private company?
EmpowerPharm is a private company. It is classified as unknown and is currently operating.
When was EmpowerPharm founded?
EmpowerPharm was founded in 2018. It employs 11 to 50 people.
Where is EmpowerPharm based?
EmpowerPharm is headquartered in Burlington, Canada, in the North America region.
Who are EmpowerPharm's main competitors?
Broad incumbents on record are Canopy Growth, Jazz Pharmaceuticals, Aurobindo Pharma and Tilray Brands. Direct peers are GW Pharmaceuticals (Jazz Pharmaceuticals), Zynerba Pharmaceuticals and Botanix Pharmaceuticals. Emerging players are Aphria (now part of Tilray), Charlotte's Web and PureForm Global.
Does EmpowerPharm have an API?
No public API is recorded for EmpowerPharm.
What industry is EmpowerPharm in?
EmpowerPharm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing, with a secondary code of HLAGAHAD, Controlled Substances / DEA-Scheduled API Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.